Bernstein Downgrades Food Giants on GLP-1 Drug Threat, Health Trends

Bernstein turned more cautious on the U.S. packaged food sector, downgrading several industry heavyweights as it warned that structural headwinds from rising GLP-1 drug adoption to regulatory scrutiny and shifting consumer preferences are likely to pressure growth and profitability for years to come.

Rating Change

Bernstein downgraded General Mills (NYSE:GIS), Kraft Heinz (NASDAQ:KHC), Conagra Brands (NYSE:CAG), Hormel Foods (NYSE:HRL), and B&G Foods (NYSE:PBG) from "Market Perform" to "Underperform," while lowering price targets for each.

Analyst Rationale

Analysts cited accelerating adoption of GLP-1 drugs (e.g., Ozempic, Wegovy), which reduce appetite and shift consumption away from processed foods. They also noted increased regulatory scrutiny on food marketing and a consumer shift toward healthier, organic alternatives.

Context

The downgrades follow a weak performance for packaged food stocks over the past year, with the S&P 500 Consumer Staples sector down about 5% in 2025. Other analysts, such as JPMorgan, have expressed similar caution but maintained their ratings.

What to Make of It

The downgrades suggest the sector may face prolonged pressure, but investors should weigh structural risks against the attractive dividend yields these companies offer.